Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript
Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 6,736,854 | $193,212,973 | +103% | 0.95% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,981,212 | $171,541,160 | +51% | 4.29% |
| 3. | Casdin Capital Eli Casdin | 5,714,775 | $163,899,747 | +216% | 16.08% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,148,657 | $147,663,483 | +92% | 1.68% |
| 5. | Deerfield Management James E. Flynn | 3,090,073 | $88,623,294 | +77% | 1.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.85 | 6,200 | Director | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | Director | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | Director | 618,181 | 2023-03-07 | Filing | |
| $22.00 | 231,819 | Director | 1,453,134 | 2023-03-07 | Filing | |
| $20.00 | 250,000 | Director | 1,221,315 | 2022-07-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.34 | 5,000 | 30,424 | 2024-04-10 | Filing | ||
| $35.33 | 5,000 | 30,424 | 2024-04-10 | Filing | ||
| $35.48 | 7,500 | 452,879 | 2024-04-10 | Filing | ||
| $37.00 | 2,155 | 15,700 | 2024-04-10 | Filing | ||
| $31.52 | 800 | 54,374 | 2024-03-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,882,086 | $426,818,226 | 0.07% | |
| 2. | 14,634,391 | $419,714,333 | 0% | |
| 3. | 12,954,314 | $371,529,727 | 0% | |
| 4. | 6,296,740 | $180,590,503 | 33.64% | |
| 5. | 6,253,361 | $179,346,393 | 0% |
News See All
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Revolution Medicine's Second Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2023 Earnings Call Transcript
Operator: Good day and welcome to Revolution Medicine's First Quarter 2023 Earnings Conference Call. As a reminder, today's conference is being recorded.
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Carl Icahn, Michael Burry, Rhenman & Partners Asset Management, Oaktree Capital Management, Revolution Medicines Inc (RVMD), Grocery Outlet Holding Corp (GO), and More
Billionaire investor Bill Ackman said the US government's move to guarantee deposits in the aftermath of Silicon Valley Bank and Signature Bank's failure is not a "not a bailout in any form".
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.
Harvard University Stock Portfolio: Top 10 Picks
Harvard Management Company was established in 1974 and manages Harvard University's endowment and financial assets.
Harvard University's Latest Portfolio: 5 Best Biotech Stock Picks
In this article, we will look at Harvard University's latest stock portfolio and list its 5 best biotech stock picks.
Hedge Fund and Insider Trading News: Bill Ackman, Mark Carhart, Ellington Management, Luxor Capital Group, Revolution Medicines Inc (RVMD), Health Sciences Acquisitions Corporation 2 (HSAQ), and More
The Federal Reserve and Chairman Jerome Powell will keep benchmark interest rates higher for longer to tame inflation, Bill Ackman tweeted Tuesday.